Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MapLight Therapeutics, Inc. is a privately held biotechnology company focused on discovering and developing precision medicines for central nervous system (CNS) disorders. The company operates within the biopharmaceutical and neuroscience drug discovery industries, with an emphasis on targeting specific neural circuits implicated in psychiatric and neurological diseases. MapLight’s approach centers on selective modulation of G protein–coupled receptors (GPCRs) to achieve therapeutic efficacy while reducing side effects commonly associated with less targeted CNS drugs.
The company was founded in 2018 by former neuroscience researchers from large pharmaceutical organizations, with the goal of applying modern neurobiology, human genetics, and circuit-based drug discovery to areas of high unmet medical need. Since inception, MapLight has advanced a pipeline of preclinical and early clinical programs targeting disorders such as depression, schizophrenia, and other neuropsychiatric conditions, positioning itself as a specialist in highly selective CNS therapeutics.
Business Operations
MapLight Therapeutics’ operations are primarily focused on research and development, with revenue generation currently centered on private capital funding rather than commercialized products. The company’s core business activities include target identification, medicinal chemistry, preclinical validation, and early-stage clinical development. Its drug discovery platform integrates human genetic data, translational biomarkers, and advanced pharmacology to improve clinical predictability in CNS drug development.
Operations are largely domestic within the United States, with laboratory and corporate functions concentrated in the San Francisco Bay Area. As of publicly available information, MapLight does not report commercial partnerships generating recurring revenue, though it engages in strategic research collaborations and utilizes external contract research organizations to support preclinical and clinical activities. Data on subsidiaries or joint ventures is inconclusive based on available public sources.
Strategic Position & Investments
Strategically, MapLight Therapeutics is focused on building a differentiated CNS pipeline by targeting GPCRs with unprecedented selectivity, aiming to address limitations of existing neuropsychiatric treatments. Growth initiatives center on advancing lead candidates into clinical trials and expanding its discovery platform to additional validated CNS targets. The company has emphasized capital efficiency and scientific rigor as core elements of its long-term strategy.
MapLight has completed multiple private financing rounds backed by life sciences–focused institutional investors, which have been used to fund pipeline expansion and platform development. The company has not disclosed any completed acquisitions of other companies, and information regarding equity investments in external portfolio companies is inconclusive based on available public sources. Its strategic investments are primarily internal, directed toward proprietary technology, talent acquisition, and clinical development capabilities.
Geographic Footprint
MapLight Therapeutics is headquartered in the United States, with its principal offices and research facilities located in the San Francisco Bay Area, California. This location places the company within a major global biotechnology hub, facilitating access to scientific talent, academic collaborators, and venture capital.
The company’s operational footprint is predominantly domestic, with no publicly disclosed international offices or manufacturing sites. However, MapLight’s research activities and clinical development strategy have global relevance, as its therapeutic programs are intended for worldwide regulatory pathways and patient populations. International operational presence beyond the U.S. is inconclusive based on available public sources.
Leadership & Governance
MapLight Therapeutics is led by an executive team with prior experience in large pharmaceutical companies and CNS drug development. The leadership emphasizes a science-driven culture focused on translational rigor, patient impact, and disciplined execution in high-risk therapeutic areas.
Key executives include:
- Christopher F. Ahern, Ph.D. – Chief Executive Officer
- Harel Weinstein, Ph.D. – Chief Scientific Officer
- Brian S. Fiske, Ph.D. – Senior Vice President, Research (role and title based on public disclosures; details may vary)
Information regarding the full board of directors, governance committees, and detailed leadership philosophy is limited in publicly available sources. Where discrepancies exist across disclosures, data is inconclusive based on available public sources.